Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.5175
-0.0124 (-2.34%)
At close: May 12, 2025, 4:00 PM
0.5175
0.00 (0.00%)
After-hours: May 12, 2025, 8:00 PM EDT
Theriva Biologics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Theriva Biologics.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Theriva Biologics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 |
---|---|---|---|
Strong Buy | 1 | 1 | 0 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 1 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 8, 2025 |
Maxim Group | Maxim Group | Strong Buy Maintains $25 → $6 | Strong Buy | Maintains | $25 → $6 | +1,059.42% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
n/a
from 55.14M
Revenue Next Year
n/a
EPS This Year
-5.63
from -19.03
EPS Next Year
-5.90
from -5.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -5.80 | -6.07 | -5.03 |
Avg | -5.63 | -5.90 | -4.89 |
Low | -5.41 | -5.66 | -4.69 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.